Clinical Trial Update: AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating the Wee1 inhibitor adavosertib (AZD1775) in women with recurrent or persistent endometrial serou…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Carcinosarcoma
• Endometrial Serous Carcinoma

Drugs mentioned

• AZD1775 (Adavosertib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Uterine Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING